Upregulation of microRNA-200a associates with tumor proliferation, CSCs phenotype and chemosensitivity in ovarian cancer

Neoplasma

Volumn 62, Issue 4, 2015, Pages 550-558

  Liu, N ^a,b   Zhong, L ^a   Zeng, J ^a   Zhang, X ^a   Yang, Q ^a   Liao, D ^a   Wang, Y ^a,a   Chen, G ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Shanghai First Maternity and Infant Health Hospital   (China)

Author keywords

Cancer stem cells; Chemosensitivity; microRNA; Ovarian cancer; Proliferation

Indexed keywords

CISPLATIN; KI 67 ANTIGEN; LENTIVIRUS VECTOR; MICRORNA 200A; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; CANCER STEM CELL; CCK8 ASSAY; CELL CYCLE ASSAY; CELL PROLIFERATION; CHEMOSENSITIVITY; COLONY FORMATION ASSAY; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIDE POPULATION ASSAY; SIDE POPULATION CELL; SPHEROID FORMATION ASSAY; TRANSGENE; TUMOR SPHEROID; TUMOR XENOGRAFT; UPREGULATION;

EID: 84943600223     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2015_066     Document Type: Article

References (22)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013 CA: a cancer. journal for clinicians 2013; 63, 11–30.
2. BAST RC, JR., HENNESSY B, MILLS GB. The biology of ovarian cancer: new opportunities for translation. Nature reviews Cancer 2009; 9, 415–428. http://dx.doi.org/10.1038/nrc2644
3. Hu X, MACDONALD DM, HUETTNER PC, FENG Z, EL NAQA IM et al. A miR-200 microRNA cluster as prog­nostic marker in advanced ovarian cancer. Gynecologic oncology 2009; 114, 457–464. http://dx.doi.org/10.1016/j.ygyno.2009.05.022
4. Eitan R, Kushnir M, Lithwick-Yanai G, DAVID MB, HOSHEN M et al. Tumor microRNA expression patterns associated with resistance to platinum based chemo­therapy and survival in ovarian cancer patients. Gynecologic oncology 2009;114, 253–259. http://dx.doi.org/10.1016/j.ygyno.2009.04.024
5. Guo R, Wu Q, Liu F, Wang Y. Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3. Oncology reports 2011; 25, 141–146.
6. Wu Q, Guo R, Lin M, Zhou B, Wang Y. MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Gynecologic oncology 2011; 122, 149–154. http://dx.doi.org/10.1016/j.ygyno.2011.03.026
7. Seve P, Dumontet C. Is class III beta-tubulin a predic­tive factor in patients receiving tubulin-binding agents? The lancet oncology 2008; 9, 168–175. http://dx.doi.org/10.1016/S1470-2045(08)70029-9
8. Feng X, Wang Z, Fillmore R, Xi Y. MiR-200, a new star miRNA in human cancer. Cancer letters 2014; 344, 166–173. http://dx.doi.org/10.1016/j.canlet.2013.11.004
9. Mateescu B, Batista L, Cardon M, Gruosso T, DeFeraudy Y et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nature medicine 2011; 17, 1627–1635. http://dx.doi.org/10.1038/nm.2512
10. Han Y, Huang H, Xiao Z, Zhang W, Cao Y et al. In­tegrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithe­lial ovarian cancer. PloS one 2012; 7, e52745. http://dx.doi.org/10.1371/journal.pone.0052745
11. CANCER GENOME ATLAS RESEARCH N. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474, 609–615. http://dx.doi.org/10.1038/nature10166
12. Lee SH, NAM HJ, KANG HJ, KWON HW, LIM YC. Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway. Eu­ropean journal of cancer 2013; 49, 3210–3218. http://dx.doi.org/10.1016/j.ejca.2013.06.025
13. KUMAR SM, LIU S, LU H, ZHANG H, ZHANG PJ et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene 2012; 31, 4898–4911. http://dx.doi.org/10.1038/onc.2011.656
14. Vathipadiekal V, Saxena D, MOK SC, HAUSCHKA PV, OZBUN L et al. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PloS one 2012; 7, e29079. http://dx.doi.org/10.1371/journal.pone.0029079
15. Hu L, Mcarthur C, JAFFE RB. Ovarian cancer stem-like side-population cells are tumorigenic and chemoresistant. British journal of cancer 2010; 102, 1276–1283. http://dx.doi.org/10.1038/sj.bjc.6605626
16. COCHRANE DR, HOWE EN, SPOELSTRA NS, RICHER JK. Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. Journal of oncology 2010; 2010, 821717.
17. Feng B, Wang R, SONG HZ, CHEN LB. MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer 2012; 118, 3365–3376.
18. Li L, Bhatia R. Stem cell quiescence Clinical cancer research: an official. journal of the American Association for Cancer Research 2011 17, 4936–4941.
19. Liu P, KUMAR IS, BROWN S, KANNAPPAN V, TAWARI PE et al. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. British journal of cancer 2013; 109, 1876–1885. http://dx.doi.org/10.1038/bjc.2013.534
20. Wang L, Mezencev R, Bowen NJ, MATYUNINA LV, MCDONALD JF. Isolation and characterization of stem-like cells from a human ovarian cancer cell line. Molecular and cellular biochemistry 2012; 363, 257–268. http://dx.doi.org/10.1007/s11010-011-1178-6
21. SCHIFF PB, FANT J, HORWITZ SB. Promotion of micro­tubule assembly in vitro by taxol. Nature 1979; 277, 665–667. http://dx.doi.org/10.1038/277665a0
22. Katsumata N, Yasuda M, Takahashi F, Isoni-­shi S, Jobo T et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374, 1331–1338. http://dx.doi.org/10.1016/S0140-6736(09)61157-0